Company News - China COSCO Shipping Energy Transportation Co., Ltd. (中远海能) has signed shipbuilding contracts with Dalian COSCO Shipping Heavy Industry, Yangzhou COSCO Shipping Heavy Industry, and Guangdong COSCO Shipping Heavy Industry for the construction of one ethylene ship and eighteen oil tankers, with a total cost of RMB 7.882 billion [1] - ZhongAn Online P&C Insurance Co., Ltd. (众安在线) reported a total original insurance premium income of approximately RMB 32.904 billion for the first eleven months [2] - R&F Properties Co., Ltd. (富力地产) achieved total sales revenue of approximately RMB 12.7 billion in the first eleven months, representing a year-on-year increase of 24.63% [3] - Yida China Holdings Limited (亿达中国) reported a contracted sales amount of approximately RMB 681 million for the first eleven months, a year-on-year decrease of 23.22% [4] - Karsen International Holdings Limited (卡森国际) has entered into a steel structure procurement contract with suppliers, involving an investment of RMB 43.5366 million [4] Clinical and Regulatory Updates - Bolex Cloud-B (拨康视云-B) successfully held a meeting after the second phase of clinical trials for CBT-004 [5] - Innovent Biologics, Inc. (复宏汉霖) has had its application for the marketing registration of Hansizhuang® combined chemotherapy for gastric cancer accepted by the National Medical Products Administration, and it has been included in the priority review [5] - CSPC Pharmaceutical Group Limited (石药集团) received approval for a new indication for Donyi® (Irinotecan Liposome Injection) for first-line treatment in patients with metastatic pancreatic cancer [5] - Heng Rui Medicine (恒瑞医药) received a clinical trial approval notice for HRS-1780 tablets [7] Investment and Acquisition Activities - AVIC Aviation Industry Corporation (中航科工) plans to acquire a 59.1816% partnership interest in Hangtou Yuhua for a consideration of RMB 202 million [8] - China Environment Resources Holdings Limited (中国环境资源) intends to acquire 90% equity in Sichuan Yuanlai Shun Recycling Resources Co., Ltd. for RMB 9 million [9] - AVIC Aviation Industry Corporation (中航科工) has proposed to implement full circulation of H-shares [10] - Yabo Technology Holdings Limited (亚博科技控股) has entered into a framework agreement with Alipay (Hangzhou) [11] Financing and Buyback Activities - Yum China Holdings, Inc. (百胜中国) has entered into a share buyback agreement with a total repurchase amount of approximately USD 460 million, including about HKD 880 million under the Hong Kong plan, as part of a plan to return USD 1.5 billion to shareholders through dividends and share buybacks by 2026 [12] - Tencent Holdings Limited (腾讯控股) repurchased approximately 1.044 million shares for about HKD 636 million, with repurchase prices ranging from HKD 601.5 to HKD 616 [13] - Xuanwu Cloud (玄武云) repurchased 6,000 shares for a total of HKD 6,467.79, with prices between HKD 1.05 and HKD 1.07 [14] - China COSCO Shipping Holdings Co., Ltd. (中远海控) repurchased approximately 4.461 million shares for about HKD 60.8605 million, with prices ranging from HKD 13.38 to HKD 13.82 [15] - Geely Automobile Holdings Limited (吉利汽车) repurchased approximately 1.362 million shares for about HKD 23.9241 million, with prices between HKD 17.29 and HKD 17.82 [16] - China Anshun Energy (中国安储能源) plans to issue a total of 524 million shares at a discount of approximately 19.12%, aiming to raise about HKD 288.2 million [16]

恒瑞医药(01276.HK)发布公告，近日，公司子公司苏州盛迪亚生物医药有限公司收到国家药品监督管理 局核准签发关于 SHR-A1811(sc)注射液的《药物临床试验批准通知书》，将于近期开展临床试验。 ...

Core Viewpoint - Jiangsu Hengrui Medicine Co., Ltd. has received approval from the National Medical Products Administration for the clinical trial of SHR-A1811(sc) injection, which will be conducted in patients with advanced solid tumors [1][2]. Group 1: Company Information - Hengrui Medicine's subsidiary, Suzhou Sediya Biopharmaceutical Co., Ltd., is responsible for the clinical trial of SHR-A1811(sc) injection [1]. - The clinical trial application for SHR-A1811(sc) injection was accepted on September 10, 2025, and has met the requirements for drug registration [2]. Group 2: Drug Information - The drug SHR-A1811(sc) is an injectable formulation intended for use in clinical trials [2]. - The approval allows for the drug to be tested specifically in patients with advanced solid tumors [2].

受理号：CXHL2500996、CXHL2500997、CXHL2500998 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025年9月11日受理的HRS9531 注射液临床试验申请符合药品注册的有关要求，同意本品开展代谢相关脂肪性肝炎的临床试验。 剂型：注射剂 申请事项：临床试验 格隆汇12月12日丨恒瑞医药(01276.HK)公告，近日，江苏恒瑞医药股份有限公司子公司福建盛迪医药有 限公司收到国家药品监督管理局核准签发关于HRS9531注射液的《药物临床试验批准通知书》，将于近 期开展临床试验。 药物名称：HRS9531注射液 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 一、药品的基本情况 中國上海 2025年12月12日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编 ...

Group 1 - Core viewpoint: Jiangsu Hengrui Medicine Co., Ltd.'s subsidiary, Ruishi Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of RSS0343 tablets, which will commence shortly [1] Group 2 - Drug name: RSS0343 tablets [2] - Dosage form: Tablet [2] - Application matter: Clinical trial [2] - Acceptance numbers: CXHL2501022, CXHL2501023, CXHL2501024, CXHL2501025 [2] - Approval conclusion: The clinical trial application for RSS0343 tablets, submitted on September 22 and 23, 2025, meets the requirements for drug registration and is approved to conduct two clinical trials [2] - Indications: Chronic sinusitis without nasal polyps and chronic obstructive pulmonary disease [2]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of RSS0343, a new oral drug targeting chronic sinusitis and chronic obstructive pulmonary disease [1] Group 1: Drug Development - RSS0343 is a self-developed small molecule Class 1 new drug with strong anti-inflammatory effects and the ability to alleviate respiratory tract-related tissue damage in animal models [1] - There are currently no similar drugs approved for market in China or internationally for the treatment of chronic sinusitis without nasal polyps and chronic obstructive pulmonary disease [1] - The total research and development investment for the RSS0343 project has reached approximately 72.28 million yuan [1]

Core Viewpoint - Heng Rui Medicine (01276) has received approval from the National Medical Products Administration for clinical trials of HRS9531 injection, a novel dual agonist targeting GIPR and GLP-1R, aimed at improving metabolic disorders and weight management [1] Group 1: Product Development - The HRS9531 injection is based on the active ingredient HRS9531, which has global independent intellectual property rights [1] - The drug is designed to regulate glucose and lipid metabolism, suppress appetite, and enhance insulin sensitivity, leading to improved blood sugar levels and weight loss [1] Group 2: Target Indication - HRS9531 injection is expected to provide comprehensive benefits for patients with metabolic dysfunction-related fatty liver disease (MASH) by improving liver lipid accumulation, reducing inflammation, and potentially improving liver fibrosis [1] - There are currently no similar drugs approved for the MASH indication globally [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年12月12日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-2 ...

HRS-1780 片是盐皮质激素受体拮抗剂，临床拟用于治疗左室射血分数≥40% 的成人心力衰竭。目前治 疗心衰的主要药物包括血管紧张素受体/脑啡肽酶抑制剂和钠-葡萄糖共转运蛋白2抑制剂等。截至目 前，HRS-1780 片相关项目累计研发投入约为6780万元。 智通财经APP讯，恒瑞医药(01276)发布公告，近日，江苏恒瑞医药股份有限公司(以下简称"公司")子公 司山东盛迪医药有限公司收到国家药品监督管理局(以下简称"国家药监局")核准签发关于HRS-1780片的 《药物临床试验批准通知书》，将于近期开展临床试验。 ...